Multiple endocrine neoplasia type 1

Changed by George Harisis, 16 Sep 2018

Updates to Article Attributes

Body was changed:

Multiple endocrine neoplasia type I (MEN1), also known as Wermer syndrome, is an autosomal dominant genetic disease that results in proliferative lesions in multiple endocrine organs, particularly the pituitary gland, islet cells of the pancreas and parathyroid glands

There are other multiple endocrine neoplasia syndromes and these are discussed separately. 

Clinical presentation

Primary hyperparathyroidism is the commonest presentation, followed by pancreatic islet cell tumour with associated hypersecretion syndromes; gastrinomas are most common and associateassociated with Zollinger-Ellison syndrome 7

Pathology

The abnormality is related to a tumour suppressor gene located in chromosome 11q13. MEN type I is an autosomal dominant syndrome characterised by 1-7:

Handy mnemonics for recalling MEN type I: 

  • PPP or PiParPanc
Associations

In addition to the aforementioned characteristic lesions involving the pituitary, parathyroid and pancreas, numerous other lesions are encountered with greater frequency in patients with MEN1. These include: 

Treatment and prognosis

Treatment is directed to each individual manifestation. These are therefore discussed separately.

Pancreatic malignancy is the leading cause of mortality in MEN type I. 

History and etymology

MEN1 was first characterised by P Wermer et al. in 1954 3.

See also

  • -<p><strong>Multiple endocrine neoplasia type I (MEN1)</strong>, also known as <strong>Wermer syndrome</strong>, is an autosomal dominant genetic disease that results in proliferative lesions in multiple endocrine organs, particularly the <a href="/articles/pituitary-gland">pituitary gland</a>, islet cells of the <a href="/articles/pancreas">pancreas</a> and <a href="/articles/parathyroid-glands">parathyroid glands</a>. </p><p>There are other <a href="/articles/multiple-endocrine-neoplasia-syndromes">multiple endocrine neoplasia </a><a href="/articles/multiple-endocrine-neoplasia-syndromes">syndromes</a> and these are discussed separately. </p><h4>Clinical presentation</h4><p><a href="/articles/primary-hyperparathyroidism">Primary hyperparathyroidism</a> is the commonest presentation, followed by pancreatic islet cell tumour with associated hypersecretion syndromes; <a href="/articles/gastrinoma">gastrinomas</a> are most common and associate with <a href="/articles/zollinger-ellison-syndrome">Zollinger-Ellison syndrome</a> <sup>7</sup>. </p><h4>Pathology</h4><p>The abnormality is related to a tumour suppressor gene located in chromosome 11q13. MEN type I is an autosomal dominant syndrome characterised by <sup>1-7</sup>:</p><ul>
  • +<p><strong>Multiple endocrine neoplasia type I (MEN1)</strong>, also known as <strong>Wermer syndrome</strong>, is an autosomal dominant genetic disease that results in proliferative lesions in multiple endocrine organs, particularly the <a href="/articles/pituitary-gland">pituitary gland</a>, islet cells of the <a href="/articles/pancreas">pancreas</a> and <a href="/articles/parathyroid-glands">parathyroid glands</a>. </p><p>There are other <a href="/articles/multiple-endocrine-neoplasia-syndromes">multiple endocrine neoplasia </a><a href="/articles/multiple-endocrine-neoplasia-syndromes">syndromes</a> and these are discussed separately. </p><h4>Clinical presentation</h4><p><a href="/articles/primary-hyperparathyroidism">Primary hyperparathyroidism</a> is the commonest presentation, followed by pancreatic islet cell tumour with associated hypersecretion syndromes; <a href="/articles/gastrinoma">gastrinomas</a> are most common and associated with <a href="/articles/zollinger-ellison-syndrome">Zollinger-Ellison syndrome</a> <sup>7</sup>. </p><h4>Pathology</h4><p>The abnormality is related to a tumour suppressor gene located in chromosome 11q13. MEN type I is an autosomal dominant syndrome characterised by <sup>1-7</sup>:</p><ul>
  • -<li><a href="/articles/carcinoid-tumours-1">carcinoid tumours </a></li>
  • +<li><a href="/articles/carcinoid-tumour-2">carcinoid tumours </a></li>

ADVERTISEMENT: Supporters see fewer/no ads

Updating… Please wait.

 Unable to process the form. Check for errors and try again.

 Thank you for updating your details.